[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.0.26. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
June 2014

The Value of Time in Assessing the Effectiveness of Newborn Screening for Congenital Adrenal Hyperplasia

Author Affiliations
  • 1Child Health Evaluation and Research Unit, Division of General Pediatrics, University of Michigan, Ann Arbor
JAMA Pediatr. 2014;168(6):515-516. doi:10.1001/jamapediatrics.2014.246

Time is precious. In newborn screening (NBS), more time is often associated with increased risk—risk to a child’s health that comes with the passing of time between NBS and diagnosis of a disorder. In their article titled “Nationwide Neonatal Screening for Congenital Adrenal Hyperplasia in Sweden: A 26-Year Longitudinal Prospective Population-Based Study,” Gidlöf et al1 show that for assessment of a program’s screening performance, more time is exceedingly valuable. By assessing the program during a 26-year period and the newborns as they grow older, the authors have challenged the notion that NBS for congenital adrenal hyperplasia (CAH) is a lost cause. Moreover, they demonstrate the value of genotyping as part of CAH NBS, especially for predicting neonatal salt-wasting crises.

First Page Preview View Large
First page PDF preview
First page PDF preview
×